Cisplatin-based chemotherapy in advanced seminoma: The Institut Gustave Roussy experience

European Journal of Cancer

Volumn 34, Issue 3, 1998, Pages 353-358

  Culine, S ^a   Abs, L ^a   Terrier Lacombe, M J ^a   Theodore C ^a   Wibault, P ^a   Droz, J P ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Advanced seminoma; Chemotherapy; Prognostic factors

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; PROTEIN P53; VINBLASTINE; VINCRISTINE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEMINOMA;

EID: 0032007373     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10070-3     Document Type: Editorial

References (27)

1. 1. Zagars GK. Management of stage I seminoma: radiotherapy. In Horwich A, ed. Testicular Cancer. Investigation and Management. London, Chapman & Hall, 1991, 83-107.
2. 2. Thomas G. Management of metastatic seminoma: role of radiotherapy. In Horwich A, ed. Testicular Cancer. Investigation and Management. London, Chapman & Hall, 1991, 117-128.
3. 3. Mason BR, Kearsley JH. Radiotherapy for stage II testicular seminoma: the prognostic influence of tumour bulk. J Clin Oncol 1988, 6, 1856-1862.
4. 4. Warde PR, Gospodarowicz M, Panzarella T, et al. Management of stage II seminoma. Proc Am Soc Clin Oncol 1996, 15, 242.
5. 5. Culine S, Kramar A, Biron P, Droz JP. Chemotherapy in adult germ cell tumors. Crit Rev Oncol Hematol 1996, 22, 229-263.
6. 6. Kaplan EL, Meier PE. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 467-471.
7. 7. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50, 163-167.
8. 8. International Germ Cell Cancer Collaborative Group. International germ cell consensus prognostic classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997, 15, 594-603.
9. 9. Fossa SD, Borge L, Aass N, Johannessen NB, Stenwig AE, Kaalhus O. The treatment of advanced metastatic seminoma: experience in 55 cases. J Clin Oncol 1987, 5, 1071-1077.
10. 10. Loehrer PJ, Birch R, Williams SD, Greco FA, Einhorn LH. Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. J Clin Oncol 1987, 5, 1212-1220.
11. 11. Logothetis CJ, Samuels ML, Ogden SL, Dexeus Fh, Chong CDK. Cyclophosphamide and sequential cisplatin for advanced seminoma: long-term followup in 52 patients. J Urol 1987, 138, 789-794.
12. 12. Tjulandin SA, Khlebnov AV, Nasirova RJ, et al. VAB-6 and cisplatin-cyclophosphamide combinations in the treatment of metastatic seminoma patients: the U.S.S.R. experience. Ann Oncol 1991, 2, 667-672.
13. 13. Mencel PJ, Motzer RJ, Mazumdar M, Vlamis V, Bajorin DJ, Bosl GJ. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 1994, 12, 120-126.
14. 14. Miller KD, Loehrer PJ, Gonin R, Einhorn LH. Salvage chemotherapy with vinblastine, ifosfamide and cisplatin in recurrent seminoma. J Clin Oncol 1997, 15, 1427-1431.
15. 15. Droz JP, Kramar A, Rey A. Prognostic factors in metastatic disease. Semin Oncol 1992, 19, 181-189.
16. 16. Shuin T, Misaki H, Kubota Y, Yao M, Hosaka M. Differential expression of protooncogenes in human germ cell tumors of the testis. Cancer 1994, 73, 1721-1727.
17. 17. Ferreiro JA. Ber-H2 expression in testicular germ cell tumors. Hum Pathol 1994, 25, 522-524.
18. 18. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992, 70, 523-526.
19. 19. Chang F, Syrjänen S, Syrjänen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995, 13, 1000-1022.
20. 20. Lewis DJ, Sesterhenn IA, McCarthy WF, Moul JW. Immunohistochemical expression of p53 tumor suppressor gene protein in adult germ cell testis tumor: clinical correlations in stage I disease. J Urol 1994, 152, 418-423.
21. 21. Riou G, Barrois M, Frost S, Terrier MJ, Théodore C, Levine AJ. The p53 and mdm-2 genes in human testicular germ-cell tumors. Molec Carcinogenesis 1995, 12, 124-128.
22. 22. Peng HQ, Hogg D, Malkin D, et al. Mutations of the p53 gene do not occur in testis cancer. Cancer Res 1993, 53, 3574-3578.
23. 23. Peng HQ, Bailey D, Bronson D, Goss PE, Hogg D. Loss of heterozygosity of tumor suppressor genes in testis cancer. Cancer Res 1995, 55, 2871-2875.
24. 24. Wei YD, Jiafu Z, Xi QS, et al. p53 gene mutations in Chinese human testicular seminoma. J Urol 1993, 150, 884-886.
25. 25. Schenkman NS, Sesterhenn IA, Washington L, et al. Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors. J Urol 1995, 154, 617-621.
26. 26. Walt H, Arrenbrecht S, Delozier-Blanchet CD, Keller PJ, Nauer R, Hedinger CE. A human testicular germ cell tumor with borderline histology between seminoma and embryonal carcinoma secreted beta-human chorionic gonadotrophin and alpha-feto-protein only as a xenograft. Cancer 1986, 58, 139-143.
27. 27. Motzer RJ, Bosl GJ, Reuter V. An immunohistochemical analysis of blood group antigens in germ cell tumors. Cancer Res 1988, 48, 5343-5347.